Tamiflu, the frontline treatment for influenza, offers no benefit for patients if it is administered in double the normal dose, a study conducted in Southeast Asia said on Thursday.
Previous studies that found Tamiflu - lab name oseltamivir - is more effective if administered swiftly after infection, have prompted suggestions that patients would also do better if they are given a higher do
